alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EXHIBIT 32.2



CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002



In connection with this Annual Report
of Mojo Data Solutions, Inc. (the “Company”), on Form 10-K for the year ended December 31, 2018, as filed with
the U.S. Securities and Exchange Commission on the date hereof, I, Daniel Sobolewski, Interim Chief Financial Officer of the
Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of
the Sarbanes-Oxley Act of 2002, that:



| | (1) | Such Annual Report on Form 10-K for the year ended December 31,
    2018, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and                                   
| | --- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| |     |                                                                                                                                                                                                                        
| | (2) | The information contained in such Annual Report on Form 10-K
    for the year ended December 31, 2018, fairly presents, in all material respects, the financial condition and
    results of operations of the Company.





|Date: January 16, 2019 | By: | /s/ Daniel Sobolewski                                     
|---------------------- | --- | ----------------------------------------------------------
|                       |     | Daniel Sobolewski                                         
|                       |     | Interim Chief Financial Officer, Mojo Data Solutions, Inc.

| |  | 
| |  |
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Reagent Resource Support Program for AIDS Vaccine Development.                    

*Date:*                         October 12, 2010.                    

*Time:*                         11 a.m. to 1 p.m.                    

*Agenda:*                         To review and evaluate contract proposals.                    

*Place:*                         National Institutes of Health, 6700B Rockledge Drive, 3147, Bethesda, MD 20817 (Telephone Conference Call).                    

*Contact Person:*                         Jane K. Battles, PhD, Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institutes of Health/NIAID, 6700B Rockledge Drive, MSC 7616, Bethesda, MD 20892-7616, 301-451-2744,                         *battlesja@mail.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: September 2, 2010.

Jennifer S. Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010-22533 Filed 9-8-10; 8:45 am]

BILLING CODE 4140-01-P
EXHIBIT 99.9 
 
 EXPERT CONSENT
 
 I hereby consent to the use of my name and reference to my name in (i) Pretium Resources Inc.’s Annual Report onForm 40-F for the year ended December 31, 2011 and (ii) the incorporation by reference in Pretium Resources Inc.’s registration statement on Form F-10 (File No. 333-179726) filed with the United States Securities and Exchange Commission.
 
 
 Very truly yours,
 
 /s/ Kenneth C. McNaughton, M.A.Sc., P.Eng.
 Kenneth C. McNaughton, M.A.Sc., P.Eng.
 
 March 12, 2012
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-END>                               SEP-30-1998
<CASH>                                         295,764
<SECURITIES>                                         0
<RECEIVABLES>                               18,659,436
<ALLOWANCES>                                   783,409
<INVENTORY>                                  1,357,342
<CURRENT-ASSETS>                            36,001,571
<PP&E>                                      29,880,237
<DEPRECIATION>                              18,704,139
<TOTAL-ASSETS>                              51,851,381
<CURRENT-LIABILITIES>                       53,194,641
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           378
<OTHER-SE>                                 (7,500,225)
<TOTAL-LIABILITY-AND-EQUITY>                51,851,381
<SALES>                                    105,764,656
<TOTAL-REVENUES>                           105,764,656
<CGS>                                       84,520,159
<TOTAL-COSTS>                               97,684,665
<OTHER-EXPENSES>                             3,073,019
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                           2,294,955
<INCOME-PRETAX>                              8,858,055
<INCOME-TAX>                                    19,755
<INCOME-CONTINUING>                          8,838,300
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 8,838,300
<EPS-PRIMARY>                                     2.35
<EPS-DILUTED>                                     2.24
        

</TABLE>
#### STATE OF NEW JERSEY v. RICKY JOHN MCMASTERS.

May 7, 1985.

Petition for certification denied.
EX-33.2
(logo) PHH Mortgage
PHH

1 Mortgage Way
Mount Laurel, NJ 08054

Luke S. Hayden
President

Telephone: (800) 446-0963 x70184
Fax: (856) 917-4278
luke.hayden@phhmortgage.com


REPORT ON ASSESSMENT OF COMPLIANCE WITH REGULATION AB
SERVICING CRITERIA

PHH Mortgage Corporation (the "Asserting Party") is responsible for assessing
compliance as of December 31, 2011 and for the period from January 1, 2011
through December 31, 2011 (the "Reporting Period") with the Servicing criteria
set forth in Section 229.1122(d) of the Code of Federal Regulations (the
"CFR"), except for criteria set forth in Section 229.1122(d)(3)(i)(c),
(d)(4)(xv) and (d)(1)(iii) of the CFR, which the Asserting Party has concluded
are not applicable to the servicing activities it performs with respect to the
transactions covered by this report (the "Applicable Servicing Criteria").
Certain of the criteria set forth in Section 229.1122(d)(2)(i), (d)(2)(ii),
(d)(4)(iv), (d)(4)(vii), (d)(4)(viii) and (d)(4)(xi) of the CFR are performed
by outsource providers on behalf of the Asserting Party; however, the Asserting
Party has monitored the outsourcing of these criteria and assumes
responsibility for compliance. The transactions covered by this report include
all non-agency loan sale agreements executed after January 1, 2006 as well as
all re-securitization transactions after January 1, 2006 for which the
Asserting Party served as servicer (the "Platform").

The Asserting Party has assessed its compliance with the Applicable Servicing
Criteria as of December 31, 2011 and for the Reporting Period and, to the best
knowledge of the signing officers below, the Asserting Party has complied, in
all material respects throughout the Reporting Period, with the Applicable
Servicing Criteria with respect to the Platform taken as a whole. Except, the
following was noted:

Standard          Description
1122(d)(4)(vii)   During the year ended December 31, 2011, it was determined
                  certain foreclosure proceedings were not concluded in
                  accordance with the published Fannie Mae foreclosure
                  timelines, although the Asserting Party maintains
                  documentation that delays beyond the published Fannie Mae
                  foreclosure timelines were for reasons and circumstances
                  outside the control of the Asserting Party as allowed by
                  Fannie Mae Servicing Guide Announcement SVC-2010-12.

Deloitte & Touche, an independent registered public accounting firm, has issued
an attestation report on the assessment of compliance with the Applicable
Servicing Criteria for the Reporting Period as set forth in this assertion.


Date: February 29, 2012


/s/ Luke Hayden
Luke Hayden
President, PHH Mortgage Corporation


/s/ Martin L. Foster
Martin L. Foster
Senior Vice President - Loan Servicing
PHH Mortgage Corporation


(logo) EQUAL HOUSING LENDER
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONSOLIDATED BALANCE SHEET AS OF APRIL 30, 2000 AND CONSOLIDATED STATEMENT OF
OPERATIONS FOR THREE MONTHS ENDED APRIL 30, 2000.
</LEGEND>
<MULTIPLIER> 1
<CURRENCY> U.S. DOLLARS

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          JAN-31-2001
<PERIOD-START>                             FEB-01-2000
<PERIOD-END>                               APR-30-2000
<EXCHANGE-RATE>                                      1
<CASH>                                          75,000
<SECURITIES>                                         0
<RECEIVABLES>                                6,879,000
<ALLOWANCES>                                         0
<INVENTORY>                                    327,000
<CURRENT-ASSETS>                             9,024,000
<PP&E>                                       6,113,000
<DEPRECIATION>                               4,620,000
<TOTAL-ASSETS>                              11,875,000
<CURRENT-LIABILITIES>                        6,131,000
<BONDS>                                        338,000
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                     14,000
<COMMON>                                       177,000
<OTHER-SE>                                   5,031,000
<TOTAL-LIABILITY-AND-EQUITY>                11,875,000
<SALES>                                      8,067,000
<TOTAL-REVENUES>                             8,067,000
<CGS>                                        7,045,000
<TOTAL-COSTS>                                7,045,000
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              37,000
<INCOME-PRETAX>                                 65,000
<INCOME-TAX>                                     4,000
<INCOME-CONTINUING>                             61,000
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    61,000
<EPS-BASIC>                                       0.01
<EPS-DILUTED>                                     0.01


</TABLE>
No. 87-6224.

#### Rogers *v.*Carver, Superintendent, Massachusetts Correctional Institution.

C. A. 1st Cir. Certiorari denied.
<PAGE>


                                                                    Exhibit 99.2


                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of IndyMac Bancorp, Inc. (the "Company")
on Form 10-Q for the period ending September 30, 2002 as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), the
undersigned, Scott Keys, Executive Vice President and Chief Financial Officer of
the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002, that:

    (1) The Report fully complies with the requirements of section 13(a) or
        15(d) of the Securities Exchange Act of 1934; and

    (2) The information contained in the Report fairly presents, in all material
        respects, the financial condition and results of operations of the
        Company.


/s/ SCOTT KEYS
---------------------------------
Scott Keys
Executive Vice President
and Chief Financial Officer
October 30, 2002
_____________ No. 95-2248WM

_____________ Sandra Dickens, * * Appellant, * * Appeal from the United States v. * District Court for the Western * District of Missouri. Shirley S. Chater, Commissioner * of Social Security * [UNPUBLISHED] Administration, * * Appellee. *

_____________ Submitted: December 12, 1995 Filed: January 8, 1996

_____________ Before FAGG, HEANEY, and WOLLMAN, Circuit Judges.

_____________ PER CURIAM. Sandra Dickens appeals the judgment entered by the district court affirming the Secretary's decision denying Dickens disability and supplemental security income benefits. After careful review of the record and the parties' briefs, we conclude the Secretary's decision is supported by substantial evidence on the record as a whole. Because an opinion by this court would have no precedential value, we affirm the district court without further discussion. See 8th Cir. R. 47B. A true copy. Attest: CLERK, U.S. COURT OF APPEALS, EIGHTH CIRCUIT.
IN THE SUPREME COURT OF THE STATE OF MONTANA

No. 23-0306

STATE OF MONTANA,

Plaintiff and Appellee,

v.

DARRIN WILLIAM MATT,

Defendant and Appellant.

ORDER

Upon consideration of Appellant’s motion for extension of time, 

and good cause appearing,

IT IS HEREBY ORDERED that Appellant is granted an extension 

of time to and including January 22, 2024, within which to prepare, file, 

and serve Appellant’s opening brief on appeal.

Electronically signed by:

Mike McGrath

Chief Justice, Montana Supreme Court

December 15 2023

12/15/2023

Case Number: DA 23-0306
Exhibit 11

              STATEMENT REGARDING COMPUTATION OF PER SHARE EARNINGS
<TABLE>
<CAPTION>

                                                    Nine Months Ended            Three Months Ended
                                                         June 30,                     June 30,
                                                 -------------------------   -------------------------
<S>                                                 <C>            <C>             <C>            <C>
Net income per share was computed as follows:       1998           1997   (A)    1998         1997    (A)
                                                 -----------   -----------   -----------   -----------
Basic:
  Net income                                     $10,667,678   $ 7,565,347   $ 3,763,139   $ 2,548,617
                                                 ===========   ===========   ===========   ===========

  Weighted average shares outstanding              5,968,340     5,803,666     5,989,838     5,963,803
                                                 ===========   ===========   ===========   ===========

  Net income per share                           $      1.79   $      1.30   $      0.63   $      0.43
                                                 ===========   ===========   ===========   ===========

Diluted:
 Net income                                      $10,667,678   $ 7,565,347   $ 3,763,139   $ 2,548,617

  Weighted average shares outstanding              5,968,340     5,803,666     5,989,838     5,963,803

  Incremental shares under stock options computed
      under the treasury stock
      method using the average market price of
      issuer's stock during the period               292,457       160,708       308,581       225,180
  Incremental shares related to long-term
      incentive compensation plan                    283,500          --         450,000          --
  Incremental shares related to issuance
      of restricted stock                            173,244       237,624       171,630       235,280
                                                 -----------   -----------   -----------   -----------
  Weighted average shares and common
      equivalent shares outstanding                6,717,541     6,201,998     6,920,049     6,424,263
                                                 ===========   ===========   ===========   ===========

    Net income per share                         $      1.59   $      1.22   $      0.54   $      0.40
                                                 ===========   ===========   ===========   ===========
</TABLE>

(A) Restated in accordance with FASB Statement No. 128, "Earnings Per Share",
implemented October 1, 1997.


                                       15
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>  This schedule contains summary financial
information extracted from Balance Sheets and Statement
of Operations for the second quarter ended June 30, 1997
Form 10Q of Delphi Film Associates V and is qualified in
its entirety by reference to such financial statements.
       
<S>                                           <C>
<PERIOD-TYPE>                          6-MOS
<FISCAL-YEAR-END>                      DEC-31-1997
<PERIOD-END>                           JUN-30-1997
<CASH>                                           255,000
<SECURITIES>                           1,236,000
<RECEIVABLES>                          401,000
<ALLOWANCES>                              0
<INVENTORY>                               0
<CURRENT-ASSETS>                          0
<PP&E>                                    0
<DEPRECIATION>                            0
<TOTAL-ASSETS>                         1,892,000
<CURRENT-LIABILITIES>                       0
<BONDS>                                   0
<COMMON>                                  0
<PREFERRED-MANDATORY>                     0
<PREFERRED>                               0
<OTHER-SE>                             1,842,000
<TOTAL-LIABILITY-AND-EQUITY>           1,892,000
<SALES>                                   0
<TOTAL-REVENUES>                        24,000
<CGS>                                     0
<TOTAL-COSTS>                             0
<OTHER-EXPENSES>                                172,000
<LOSS-PROVISION>                          0
<INTEREST-EXPENSE>                        0
<INCOME-PRETAX>                             53,000
<INCOME-TAX>                              0
<INCOME-CONTINUING>                       0
<DISCONTINUED>                            0
<EXTRAORDINARY>                           0
<CHANGES>                                 0
<NET-INCOME>                                     53,000
<EPS-PRIMARY>                                        7.00
<EPS-DILUTED>                             0
        

</TABLE>
<PAGE>

                                                                         Page 15


                                                                    EXHIBIT 32.2

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Brunswick Bancorp and subsidiaries
(the "company") on Form 10-Q for the period ending June 30, 2006 as filed with
the Securities and Exchange Commission on the date hereof (the "Report"), I
Thomas Fornale, Chief Financial Officer of the Company, certify, pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that:

     1.   The Report fully complies with the requirements of section 13(a) or
          15(d) of the Securities Exchange Act of 1934; and

     2.   The information contained in the Report fairly presents, in all
          material respects, the financial condition and result of operations of
          the company.


Date: 07/25/06                          /s/ Thomas Fornale
                                        ----------------------------------------
                                        Thomas Fornale
                                        Chief Financial Officer
Exhibit 99.36
 MATERIAL CHANGE REPORT
 Regulation 51-102 Respecting Continuous Disclosure Obligations
Form 51-102F3
 1.
    
    NAME AND ADDRESS OF COMPANY:THERATECHNOLOGIES INC.
2310 Alfred-Nobel Boulevard
Montreal, Québec
Canada H4S 2B42.
    
    DATE OF MATERIAL CHANGE:December 6, 20103.
    
    NEWS RELEASE:A news release was issued concerning this material change on December 6, 2010 on
Marketwire. A copy of the news release is available at SEDAR website at www.sedar.com.4.
    
    SUMMARY OF MATERIAL CHANGE:On December 6, 2010, Theratechnologies Inc. (the Company) announced the execution of a
distribution and licensing agreement (the Agreement) with Sanofi-Aventis (Sanofi) for
the commercialization rights to EGRIFTA® (tesamorelin for injection) in Latin
America, Africa and the Middle East for the treatment of excess abdominal fat in
HIV-infected patients with lipodystrophy.5.
    
    FULL DESCRIPTION OF MATERIAL CHANGE:On December 6, 2010, the Company announced the execution of the Agreement with Sanofi for
the commercialization rights to EGRIFTA® (tesamorelin for injection) in Latin
America, Africa and the Middle East for the treatment of excess abdominal fat in
HIV-infected patients with lipodystrophy.Under the terms of the Agreement, the Company will be responsible to supply
EGRIFTA® to Sanofi. Sanofi will buy EGRIFTA® from the Company at
an undisclosed selling price. The Company has kept all future development rights to
EGRIFTA® and will be responsible for conducting additional research and
development for any additional programs. Sanofi will be responsible to conduct all
regulatory activities in the aforementioned territories in connection with EGRIFTA®for the treatment of excess abdominal fat in HIV-infected patients with
lipodystrophy, including seeking the approval of EGRIFTA®in the different
countries. The Company granted Sanofi an option to commercialize EGRIFTA®in
the aforementioned territories for other uses.6.
    
    RELIANCE ON SUBSECTION 7.1(2) OFREGULATION 51-102:Not applicable.7.
    
    OMITTED INFORMATION:Not applicable.




---



##### 



8.
    
    SENIOR OFFICER:For further information, contact Jocelyn Lafond, Vice President, Legal Affairs, and
Corporate Secretary of Theratechnologies Inc., at (514) 336-4804, ext. 288.9.
    
    DATE OF REPORT:December 16, 2010.
 - 2 -